Baruch D. Kuppermann

picture of Baruch D. Kuppermann

Roger F. Steinert Professor and Chair, Department of Ophthalmology
School of Medicine

Director, Gavin Herbert Eye Institute
School of Medicine

Joint Appointment, Professor, Department of Biomedical Engineering
The Henry Samueli School of Engineering

Co-Director, Center for Translational Vision Research
School of Medicine


M.D., University of Miami, Florida, 1985
Ph.D., California Institute of Technology, 1983, Neuroscience

Phone: Appointments (949) 824-2020; Academic Office (949) 824-8089
Fax: (949) 824-4015
Email: bdkupper@hs.uci.edu

University of California, Irvine
Gavin Herbert Eye Institute
850 Health Sciences Road
Mail Code: 4375
Irvine, CA 92697
Research Interests
1-Pathophysiology of age-related macular degeneration (AMD) using cell culture models of the retina 2-Developing & evaluating drug delivery systems for retinal diseases 3-Clinical trial development for retinal diseases including diabetic retinopathy & AMD
URLs
Research Abstract
Baruch D. Kuppermann, M.D., Ph.D., is the Roger F. Steinert Professor, Chair of the Department of Ophthalmology, and Director of the Gavin Herbert Eye Institute at the University of California, Irvine. He also holds a joint appointment with the Department of Biomedical Engineering at UC Irvine.

After completing his Ph.D. in neuroscience at the California Institute of Technology, Dr. Kuppermann went on to earn an M.D. at the University of Miami, and completed fellowships in Retina at both St. Joseph’s, and at the University of California, San Diego.

Dr. Kuppermann’s laboratory research focuses on assessing the toxicity of drugs on retinal cells in culture, including various vital stains, steroids, and anti-VEGF compounds. More recently, his lab has modified its focus to study the effect of mitochondrial genetics on retinal diseases such as age-related macular degeneration and diabetic macular edema. He is active in the development of drug delivery systems for the posterior segment through collaborative work with the Department of Biomedical Engineering at UC Irvine, for which he holds several patents. Dr. Kuppermann is also co-director of the Center for Translational Vision Research at UC Irvine, which is focused on developing new treatments for blinding retinal conditions.

Dr. Kuppermann is a well-known teacher and lecturer, having given numerous named lectures and been an invited visiting professor at many academic institutions. He has published over 200 peer-reviewed articles in the medical literature, and over 50 book chapters. He is also strongly involved in clinical research, having served as Principal Investigator in many trials evaluating new drugs and technologies for the treatment of age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, retinitis pigmentosa, and other diseases of the posterior segment.

Dr. Kuppermann is listed as one of the best doctors in America, as well as one of the "Best Ophthalmologists in Orange County" by Orange Coast Magazine. He is a peer reviewer for the American Journal of Ophthalmology, Archives of Ophthalmology, Investigative Ophthalmology and Visual Science, Journal of Infectious Diseases, Lancet, Ophthalmology, Retina, and Survey of Ophthalmology. He serves on the Editorial Board of the journal Retina, as well as the Brazilian Archives of Ophthalmology, Brazilian Journal of Ophthalmology, and Retina Today. Dr. Kuppermann also serves on the Board of Directors of the Armenian EyeCare Project.
Publications
Peer-reviewed Publications 2017-2021
 
Sharma A, Parachuri N, Kumar N, Saboo B, Tripathi HN, Kuppermann BD, Bandello F. Semaglutide and the risk of diabetic retinopathy-current perspective. Eye (Lond). 2021 Aug 9. doi: 10.1038/s41433-021-01741-5. Epub ahead of print. PMID: 34373613.
 
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Faricimab: Two in the Bush Is Proving Better than One in the Hand? Ocul Immunol Inflamm. 2021 Jul 9:1-3. doi: 10.1080/09273948.2021.1931350. Epub ahead of print. PMID: 34242102.
 
Boyer DS, Gonzalez VH, Kunimoto DY, Maturi RK, Roe RH, Singer MA, Xavier S, Kornfield JA, Kuppermann BD, Quiroz-Mercado H, Aubel J, Karageozian HL, Park JY, Karageozian VH, Karageozian L, Sarayba MA, Kaiser PK. Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial. Ophthalmic Surg Lasers Imaging Retina. 2021 Jun;52(6):327-335. doi: 10.3928/23258160-20210528-05. Epub 2021 Jun 1. PMID: 34185587.
 
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study). Eye (Lond). 2021 Jun 22. doi: 10.1038/s41433-021-01616-9. Epub ahead of print. PMID: 34158653.
 
Sheth JU, Gopal L, Gillies M, Khatri M, Kuppermann B, Roy R, Chawla S, Rajendran A, Narayanan R. Vitreoretinal Society of India practice pattern survey 2020: Medical retina. Indian J Ophthalmol. 2021 Jun;69(6):1430-1439. doi: 10.4103/ijo.IJO_2573_20. PMID: 34011714; PMCID: PMC8302292.
 
Prakash S, Srivastava R, Coulon PG, Dhanushkodi NR, Chentoufi AA, Tifrea DF, Edwards RA, Figueroa CJ, Schubl SD, Hsieh L, Buchmeier MJ, Bouziane M, Nesburn AB, Kuppermann BD, BenMohamed L. Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan- Coronavirus Vaccines. J Immunol. 2021 Jun 1;206(11):2566-2582. doi: 10.4049/jimmunol.2001438. Epub 2021 Apr 28. PMID: 33911008.
 
Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Terms non-exudative and non-neovascular: awaiting entry at the doors of AMD reclassification. Graefes Arch Clin Exp Ophthalmol. 2021 Jun;259(6):1381-1383. doi: 10.1007/s00417-021-05164-6. Epub 2021 Mar 21. PMID: 33744982.
 
Sharma A, Kumar N, Parachuri N, Kuppermann BD, Bandello F, Regillo CD, Boyer D, Nguyen QD. Brolucizumab-foreseeable workflow in the current scenario. Eye (Lond). 2021 Jun;35(6):1548-1550. doi: 10.1038/s41433-020-01324-w. Epub 2021 Feb 2. PMID: 33531697; PMCID: PMC8169919.
 
Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Vortex vein anastomosis and pachychoroid-an evolving understanding. Eye (Lond). 2021 Jun;35(6):1545-1547. doi: 10.1038/s41433-021-01423-2. Epub 2021 Jan 29. PMID: 33514903; PMCID: PMC8169894.
 
Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye (Lond). 2021 May;35(5):1292-1294. doi: 10.1038/s41433-020-01227-w. Epub 2020 Oct 20. PMID: 33082532; PMCID: PMC8182886.
 
Hamid MA, Moustafa MT, Nashine S, Costa RD, Schneider K, Atilano SR, Kuppermann BD, Kenney MC. Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells. Cells. 2021 Apr 12;10(4):878. doi: 10.3390/cells10040878. PMID: 33921543; PMCID: PMC8069662.
 
Hamid MA, Abdelfattah NS, Salamzadeh J, Abdelaziz STA, Sabry AM, Mourad KM, Shehab AA, Kuppermann BD. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Int J Retina Vitreous. 2021 Apr 1;7(1):26. doi: 10.1186/s40942-021-00299-4. PMID: 33795022; PMCID: PMC8017745.
 
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Biosimilars for Retinal Diseases: An Update. Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9. PMID: 33309691.
 
Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo C, Chakravarthy U. Fluid-based prognostication in n-AMD: Type 3 macular neovascularisation needs an analysis in isolation. Br J Ophthalmol. 2021 Mar;105(3):297-298. doi: 10.1136/bjophthalmol-2020-318128. Epub 2020 Dec 8. PMID: 33293272.
 
Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A, Sadda SR, Sarraf D. Understanding the Mechanisms of Fluid Development in Age- Related Macular Degeneration. Ophthalmol Retina. 2021 Feb;5(2):105-107. doi: 10.1016/j.oret.2020.09.016. PMID: 33549199.
 
Sharma A, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD, Chakravarthy U. Notion of tolerating subretinal fluid in neovascular AMD: understanding the fine print before the injection pause. Br J Ophthalmol. 2021 Feb;105(2):149-150. doi: 10.1136/bjophthalmol-2020-317933. Epub 2020 Sep 26. PMID: 32980815.
 
Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S, López FJ; Brimo DDS Gen 1 Study Group. PHASE 2 STUDY OF THE SAFETY AND EFFICACY OF BRIMONIDINE DRUG DELIVERY SYSTEM (BRIMO DDS) GENERATION 1 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION. Retina. 2021 Jan 1;41(1):144-155. doi: 10.1097/IAE.0000000000002789. PMID: 32134802.
 
Sharma A, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Regillo CD. Brolucizumab: the road ahead. Br J Ophthalmol. 2020 Dec;104(12):1631-1632. doi: 10.1136/bjophthalmol-2020-317528. Epub 2020 Aug 22. PMID: 32829303.
 
Sharma A, Bandello F, Loewenstein A, Kuppermann BD, Lanzetta P, Zur D, Hilely A, Iglicki M, Veritti D, Wang A, Miassi F, Bellocq D, Zacharias LC, Makam D, Kumar N, Parachuri N, Barriera AK, Sharma R, Faridi H, Mathis T, Kodjikian L. Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. Int Ophthalmol. 2020 Nov;40(11):3067-3075. doi: 10.1007/s10792-020-01491-5. Epub 2020 Jul 1. PMID: 32613461.
 
Neekhra A, Tran J, Esfahani PR, Schneider K, Pham K, Sharma A, Chwa M, Luthra S, Gramajo AL, Mansoor S, Kuppermann BD, Kenney MC. Memantine, Simvastatin, and Epicatechin Inhibit 7-Ketocholesterol-induced Apoptosis in Retinal Pigment Epithelial Cells But Not Neurosensory Retinal Cells In Vitro. J Ophthalmic Vis Res. 2020 Oct 25;15(4):470-480. doi: 10.18502/jovr.v15i4.7781. PMID: 33133437; PMCID: PMC7591846.
 
Kumar N, Bandello F, Kuppermann BD, Sharma A. Comment on: 'Recent advances in anterior chamber angle imaging'. Eye (Lond). 2020 Oct;34(10):1939. doi: 10.1038/s41433-020-0791-6. Epub 2020 Feb 5. Erratum in: Eye (Lond). 2020 Aug 5;: PMID: 32024971; PMCID: PMC7608238.
 
Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab and immunogenicity. Eye (Lond). 2020 Oct;34(10):1726-1728. doi: 10.1038/s41433-020-0853-9. Epub 2020 Apr 6. PMID: 32251366; PMCID: PMC7608337.
 
Prakash S, Srivastava R, Coulon PG, Dhanushkodi NR, Chentoufi AA, Tifrea DF, Edwards RA, Figueroa CJ, Schubl SD, Hsieh L, Buchmeier MJ, Bouziane M, Nesburn AB, Kuppermann BD, BenMohamed L. Genome-Wide Asymptomatic B-Cell, CD4 + and CD8 + T-Cell Epitopes, that are Highly Conserved Between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Immune Targets for Pre-Emptive Pan-Coronavirus Vaccines. bioRxiv [Preprint]. 2020 Sep 28:2020.09.27.316018. doi: 10.1101/2020.09.27.316018. Update in: J Immunol. 2021 Apr 28;: PMID: 33024971; PMCID: PMC7536874.
 
Patil J, Patil L, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Sharma A. Smartphone based ROP (S-ROP) screening-opportunities and challenges. Eye (Lond). 2020 Sep;34(9):1512-1514. doi: 10.1038/s41433-020-0913-1. Epub 2020 Apr 28. PMID: 32346107; PMCID: PMC7608357.
 
Sheth J, Anantharaman G, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A, Sharma A. Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. Eye (Lond). 2020 Sep;34(9):1501-1503. doi: 10.1038/s41433-020-0886-0. Epub 2020 Apr 23. PMID: 32327739; PMCID: PMC7608197.
 
Sharma A, Parachuri N, Kumar N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-another anti-VEGF or beyond. Eye (Lond). 2020 Sep;34(9):1499-1500. doi: 10.1038/s41433-020-0888-y. Epub 2020 Apr 21. PMID: 32317791; PMCID: PMC7608128.
 
Kumar N, Bandello F, Kuppermann BD, Sharma A. Correction: Comment on: 'Recent advances in anterior chamber angle imaging'. Eye (Lond). 2020 Aug 5. doi: 10.1038/s41433-020-1120-9. Online ahead of print. PMID: 32760008
 
Sharma A, Bandello F, Loewenstein A, Kuppermann BD, Lanzetta P, Zur D, Hilely A, Iglicki M, Veritti D, Wang A, Miassi F, Bellocq D, Zacharias LC, Makam D, Kumar N, Parachuri N, Barriera AK, Sharma R, Faridi H, Mathis T, Kodjikian L. Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study. Int Ophthalmol. 2020 Jul 1. doi: 10.1007/s10792-020-01491-5. Online ahead of print. PMID: 32613461
 
Sane SS, Ali MH, Kuppermann BD, Narayanan R. Comparative study of pars plana vitrectomy with or without intravitreal dexamethasone implant for idiopathic epiretinal membrane. Indian J Ophthalmol. 2020 Jun;68(6):1103-1107. doi: 10.4103/ijo.IJO_1045_19. PMID: 32461441
 
Patil J, Patil L, Parachuri N, Kumar N, Bandello F, Kuppermann BD, Loewenstein A, Sharma A. Smartphone based ROP (S-ROP) screening-opportunities and challenges. Eye (Lond). 2020 Apr 28. doi: 10.1038/s41433-020-0913-1. Online ahead of print. PMID: 32346107
 
Sheth J, Anantharaman G, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A, Sharma A. Pachydrusen: the epidemiology of pachydrusen and its relevance to progression of pachychoroid disease spectrum. Eye (Lond). 2020 Apr 23. doi: 10.1038/s41433-020-0886-0. Online ahead of print.PMID: 32327739
 
Sharma A, Parachuri N, Kumar N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-another anti-VEGF or beyond. Eye (Lond). 2020 Apr 21. doi: 10.1038/s41433-020-0888-y. Online ahead of print.PMID: 32317791
 
Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab and immunogenicity. Eye (Lond). 2020 Apr 6. doi: 10.1038/s41433-020-0853-9. Online ahead of print. PMID: 32251366
 
Sharma A, Parachuri N, Kumar N, Sharma R, Bandello F, Kuppermann BD, Loewenstein A. Brolucizumab-key learnings from HAWK and HARRIER. Eye (Lond). 2020 Mar 13. doi: 10.1038/s41433-020-0842-z. Online ahead of print.PMID: 32203242 No abstract available.
 
Sharma A, Kumar N, Parachuri N, Sharma R, Bandello F, Kuppermann BD, Regillo CD. Brolucizumab and fluid in neovascular age-related macular degeneration (n-AMD). Eye (Lond). 2020 Mar 4. doi: 10.1038/s41433-020-0831-2. Online ahead of print. PMID: 32132677
 
Kuppermann BD, Patel SS, Boyer DS, Augustin AJ, Freeman WR, Kerr KJ, Guo Q, Schneider S, López FJ. Phase 2 study of the safety and efficacy of Brimonidine Drug Delivery System (Brimo DDS) Generation 1 in patients with geographic atrophy secondary to age-related macular degeneration. Retina. 2020 Mar 3. doi: 10.1097/IAE.0000000000002789. Online ahead of print. PMID: 32134802
 
Kumar N, Francesco B, Kuppermann BD, Sharma A. Comment on: 'Recent advances in anterior chamber angle imaging'. Eye (Lond). 2020 Feb 5. doi: 10.1038/s41433-020-0791-6. Online ahead of print. PMID: 32024971
 
Nashine S, Nesburn AB, Kuppermann BD, Kenney MC. Role of Resveratrol in Transmitochondrial AMD RPE Cells. Nutrients. 2020 Jan 6;12(1). pii: E159. doi: 10.3390/nu12010159. PMID: 31935891
 
Cáceres-Del-Carpio J, Moustafa MT, Toledo-Corral J, Hamid MA, Atilano SR, Schneider K, Fukuhara PS, Costa RD, Norman JL, Malik D, Chwa M, Boyer DS, Limb GA, Kenney MC, Kuppermann BD. In vitro response and gene expression of human retinal Müller cells treated with different anti-VEGF drugs. Exp Eye Res. 2020 Jan 3;191:107903. doi: 10.1016/j.exer.2019.107903. [Epub ahead of print] No abstract available. PMID: 31904361
 
Sharma A, Faridi H, Kumar N, Parachuri N, Sharma R, Kuppermann B, Bandello F, Loewenstein A, Regillo C. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: a real-world data. Eye (Lond). 2019 Dec 16. doi: 10.1038/s41433-019-0745-z. [Epub ahead of print] No abstract available. PMID: 31844168
 
Sharma A, Bilong Y, Patil J, Katte JC, Ahmad Khaqan H, Kumar Gupta N, Patel A, Sundaramoorthy SK, Madhusudan RJ, Vidhya N, Lekha T, Shah PK, Saravanan VR, Dharwadkar SS, Rishi P, Franco MFE, Chelo D, Kagmeni G, Assumpta Bella L, Kuppermann BD. MIIRetCam (Make In India Retina Camera) assisted retinal imaging in paediatric patients: Useful, artefacts, learning curve. J Fr Ophtalmol. 2020 Jan;43(1):e35-e38. doi: 10.1016/j.jfo.2019.09.003. Epub 2019 Dec 16. No abstract available. PMID: 31837894
 
Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: Combating the nocebo effect. Eye (Lond). 2019 Nov 29. doi: 10.1038/s41433-019-0722-6. [Epub ahead of print] No abstract available. PMID: 31784703
 
Sharma A, Kumar N, Kuppermann BD, Bandello F, Lowenstein A. Faricimab: expanding horizon beyond VEGF. Eye (Lond). 2019 Nov 6. doi: 10.1038/s41433-019-0670-1. [Epub ahead of print] No abstract available. PMID: 31695160
 
Sharma A, Kumar N, Kuppermann BD, Francesco B. Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neo-vascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019; 126:1141-1154). Ophthalmology. 2019 Nov;126(11):e87-e88. doi: 10.1016/j.ophtha.2019.06.019. No abstract available. PMID: 31635710
 
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Ophthalmic biosimilars and biologics-role of endotoxins. Eye (Lond). 2019 Oct 16. doi: 10.1038/s41433-019-0636-3. [Epub ahead of print] No abstract available. PMID: 31619778
 
Sharma A, Kuppermann BD, Bandello F, Lanzetta P, Zur D, Park SW, Yu HG, Saravanan VR, Zacharias LC, Barreira AK, Iglicki M, Miassi F, Veritti D, Tsao S, Makam D, Jain N, Lowenstein A. Intraocular pressure (IOP) after intravitreal dexamethasone implant (Ozurdex) amongst different geographic populations-GEODEX-IOP study. Eye (Lond). 2019 Sep 30. doi: 10.1038/s41433-019-0616-7. [Epub ahead of print] PMID: 31570814
 
Sharma A, Kumar N, Kuppermann BD, Bandello F. Abicipar pegol: the non-monoclonal antibody anti-VEGF. Eye (Lond). 2019 Sep 30. doi: 10.1038/s41433-019-0670-8. [Epub ahead of print] No abstract available. PMID: 31570812
 
Sharma A, Kumar N, Kuppermann BD, Bandello F. Brolucizimab-leading an era of structural revolution for long-term VEGF suppression. Eye (Lond). 2019 Sep 19. doi: 10.1038/s41433-019-0583-z. [Epub ahead of print] No abstract available. PMID: 3157892
 
Sharma A, Kumar N, Kuppermann BD, Lowenstein A, Bandello F. Brolucizumab: is extended VEGF suppression on the horizon? Eye (Lond). 2019 Sep 16. doi: 10.1038/s41433-019-0582-0. [Epub ahead of print] No abstract available. PMID: 31527765
 
Nashine S, Subramaniam SR, Chwa M, Nesburn A, Kuppermann BD, Federoff H, Kenney MC. PU-91 drug rescues human age-related macular degeneration RPE cells; implications for AMD therapeutics. Aging (Albany NY). 2019 Sep 2. doi: 10.18632/aging.102179. [Epub ahead of print] PMID: 31477635
 
Sharma A, Kumar N, Kuppermann BD, Francesco B, Lowenstein A. Ophthalmic biosimilars: Lessons from India. Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19. No abstract available. PMID: 31332154
 
Sharma A, Parachuri N, Kumar N, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Subfoveal Neurosensory Detachment Flattening and Observe (SNF-Ob): A Novel Approach in Diabetic Macular Edema Management: A Potential Cost-Effective Treatment Strategy to Be Explored. Ophthalmol Retina. 2019 Jul 10. pii: S2468-6530(19)30458-0. doi: 10.1016/j.oret.2019.06.016. [Epub ahead of print] No abstract available. PMID: 31451440
 
Sharma A, Kumar N, Kuppermann BD, Bandello F, Loewenstein A. Understanding biosimilars and its regulatory aspects across the globe: an ophthalmology perspective. Br J Ophthalmol. 2019 Jul 17. pii: bjophthalmol-2019-314443. doi: 10.1136/bjophthalmol-2019-314443. [Epub ahead of print] Review. PMID: 31315829
 
Sharma A, Goyal A, Bilong Y, Shah P, Banker A, Kumar N, Sharma R, Kuppermann BD, Bandello F. Comparison of a Smartphone-Based Photography Method with Indirect Ophthalmoscopic Assessment in Referable Retinopathy of Prematurity: A Smart Retinopathy of Prematurity Model Pilot Study. Ophthalmol Retina. 2019 Jun 22. pii: S2468-6530(19)30313-6. doi: 10.1016/j.oret.2019.06.006. [Epub ahead of print]. PMID: 31422107
 
Nashine S, Nesburn AB, Kuppermann BD, Kenney MC. Age-related macular degeneration (AMD) mitochondria modulate epigenetic mechanisms in retinal pigment epithelial cells. Exp Eye Res. 2019 Jun 18:107701. doi: 10.1016/j.exer.2019.107701. [Epub ahead of print]. PMID: 31226340
 
Sharma A, Kumar N, Parachuri N, Kuppermann BD, Francesco B, Regillo CD. Ranibizumab port delivery system (RPDS): realising long awaited dream of prolonged VEGF suppression. Eye (Lond). 2019 Jun 5. doi: 10.1038/s41433-019-0479-y. [Epub ahead of print]. PMID: 31165769
 
Sharma A, Kumar N, Kuppermann BD, Francesco B, Loewenstein A. Biotherapeutics and immunogenicity: ophthalmic perspective. Eye (Lond). 2019 Apr 9. doi: 10.1038/s41433-019-0434-y. [Epub ahead of print]. PMID: 30967643
 
Sharma A, Kumar N, Kuppermann BD, Francesco B, Loewenstein A. Biologics, biosilimars, and biobetters: different terms or different drugs? Eye (Lond). 2019 Mar 7. doi: 10.1038/s41433-019-0391-5. [Epub ahead of print] No abstract available. PMID: 30846867
 
Nashine S, Kanodia R, Nesburn AB, Soman G, Kuppermann BD, Kenney MC. Nutraceutical effects of Emblica officinalis in age-related macular degeneration. Aging (Albany NY). 2019 Feb 21;11(4):1177-1188. doi: 10.18632/aging.101820. PMID: 30792375
 
Hamid MA, Mehta MC, Kuppermann BD. Multimodal imaging in a patient with Prader-Willi syndrome. Int J Retina Vitreous. 2018 Nov 30;4:45. doi: 10.1186/s40942-018-0147-6. eCollection 2018.
 
Sharma A, Reddy P, Kuppermann BD, Bandello F, Lowenstein A. Biosimilars in ophthalmology: "Is there a big change on the horizon?" Clin Ophthalmol. 2018 Oct 24;12:2137-2143. doi: 10.2147/OPTH.S180393. eCollection 2018. Review.
 
Sapkal AU, Nashine S, Mansoor S, Sharma VR, Ramirez CA, Migon RZ, Gupta NK, Chwa M, Kuppermann BD, Kenney MC. Protective Effects of 17ß-Estradiol on Benzo(e) pyrene[B(e)P]-induced Toxicity in ARPE-19 cells. J Ophthalmic Vis Res. 2018 Oct-Dec;13(4):419-425. doi: 10.4103/jovr.jovr_16_18.
 
Hamid MA, Moustafa MT, Càceres-Del-Carpio J, Kuppermann BD, Kenney MC. Effects of Antiangiogenic Drugs on Expression Patterns of Epigenetic Pathway Genes. Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 15;49(10):S29-S33. doi: 10.3928/23258160-20180814-05.
 
Tsao SW, Gabriel R, Thaker K, Kuppermann BD, Kenney MC. Effects of Brimonidine on Retinal Pigment Epithelial Cells and Müller Cells Exposed to Amyloid-Beta 1-42 Peptide In Vitro. Ophthalmic Surg Lasers Imaging Retina. 2018 Oct 15;49(10):S23-S28. doi: 10.3928/23258160-20180814-04.
 
Nashine S, Cohen P, Nesburn AB, Kuppermann BD, Kenney MC. Characterizing the protective effects of SHLP2, a mitochondrial-derived peptide, in macular degeneration. Sci Rep. 2018 Oct 11;8(1):15175. doi: 10.1038/s41598-018-33290-5.
 
Singer MA, Miller DM, Gross JG, Greven CM, Kapik B, Bailey C, Ghanchi F, Kuppermann BD. Visual Acuity Outcomes in Diabetic Macular Edema With Fluocinolone Acetonide 0.2 µg/Day Versus Ranibizumab Plus Deferred Laser (DRCR Protocol I). Ophthalmic Surg Lasers Imaging Retina. 2018 Sep 1;49(9):698-706. doi: 10.3928/23258160-20180831-08.
 
Sharma A, Dongre P, Bellala K, Reddy P, Kuppermann BD, Francesco B. Role of retinal image-based counseling in the treatment of peripheral retinal lesions. Eye (Lond). 2018 Aug 17. doi: 10.1038/s41433-018-0196-y. [Epub ahead of print].
 
Riazi-Esfahani M, Kuppermann BD, Kenney MC. The Role of Mitochondria in AMD: Current Knowledge and Future Applications. J Ophthalmic Vis Res. 2017 Oct-Dec;12(4):424-428. doi: 10.4103/jovr.jovr_182_17.
 
Moustafa MT, Ramirez C, Schneider K, Atilano SR, Limb GA, Kuppermann BD, Kenney MC. Protective Effects of Memantine on Hydroquinone-Treated Human Retinal Pigment Epithelium Cells and Human Retinal Müller Cells. J Ocul Pharmacol Ther. 2017 Oct;33(8):610-619. doi: 10.1089/jop.2016.0129.
 
Nashine S, Cohen P, Chwa M, Lu S, Nesburn AB, Kuppermann BD, Kenney MC. Humanin G (HNG) protects age-related macular degeneration (AMD) transmitochondrial ARPE-19 cybrids from mitochondrial and cellular damage. Cell Death Dis. 2017 Jul 20;8(7):e2951. doi: 10.1038/cddis.2017.348.
 
Regillo CD, Callanan DG, Do DV, Fine HF, Holekamp NM, Kuppermann BD, Singer MA, Singh RP. Use of Corticosteroids in the Treatment of Patients With Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel. Ophthalmic Surg Lasers Imaging Retina. 2017 Apr 1;48(4):291-301. doi: 10.3928/23258160-20170329-03.
Grants
“SAPPHIRE: A Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Conjunction with Intravitreal Aflibercept in Subjects with Retinal Vein Occlusion”. Clearside Biomedical, Inc. September 2017-January 2019.
“An Extension Study of JC-01 Evaluating Long-Term Safety of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa (RP) (JC-01E)”. CIRM. 2017-2019.
“A Phase 2, Randomised, Double-Masked, Sham-Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (pvd) in Subjects with Non-Proliferative Diabetic Retinopathy (NPDR) (Circle)”. Thrombogenics. January 2017- December 2019.
“A Phase 3, Double-Masked, Randomized, Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy”. Regeneron. February 2017 – January 2020.
“Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-related Macular Degeneration”. Allergan. March 2016 – May 2020.
“Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration”. Ohr. January 2017 – December 2020.
“RPB Unrestricted Grant”. Research to Prevent Blindness. January 2019-December 2023.
“ISIS 696844-CS5: A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)”. Ionis Pharmaceuticals. November 2019-December 2021.
“CRTH258C2301: An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion (RAPTOR)”. Novartis Pharmaceuticals. August 2019-December 2021.
“CRTH258C2302n Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN)”. Novartis Pharmaceuticals. August 2019-December 2021.
“UCI Eye Mobile for Children”. The Doyle Foundation. April 2021-December 2022.
“A Phase 2 Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)”. Ionis Pharmaceuticals Inc. April 2020-April 2023.
“A Phase 3 Multicenter, Randomized, Double-masked, Sham Controlled Clinical Trial to assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration”. IVERIC BIO, Inc. December 2020-November 2023.
Professional Societies
American Academy of Ophthalmology
Association of University Professors of Ophthalmology
American Ophthalmological Society
American Society of Retina Specialists
Club Jules Gonin
European Society of Retina Specialists
Macula Society
Pan American Association of Ophthalmology
Retina Society
Association for Research in Vision and Ophthalmology
American Medical Association
Last updated
10/07/2021